Merus to Present at the Jefferies Virtual London Healthcare Conference

Rhea-AI Summary

Merus (Nasdaq:MRUS), a clinical-stage oncology company, announced that CEO Dr. Bill Lundberg will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 14:40 GMT. A live webcast of the presentation will be accessible on the company's Investors page, with an archived version available for a limited time.

Merus specializes in developing innovative multispecific antibodies known as Biclonics® and Triclonics™ that demonstrate characteristics similar to traditional human monoclonal antibodies.

News Market Reaction – MRUS

+3.88%

+3.88% Session move

In the trading session that priced this news, MRUS gained 3.88%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics^® and Triclonics™), today announced that Bill Lundberg, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 at 14:40 p.m. GMT/9:40 a.m. ET.

A live webcast of the presentation will be available on the Investors page of the Company's website, http://www.merus.nl/. An archived presentation will be available on the Merus website for a limited time.

About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, www.merus.nl and https://twitter.com/MerusNV.

FAQ

When is Merus' participation in the Jefferies Virtual London Healthcare Conference?

Merus will participate in the Jefferies Virtual London Healthcare Conference on November 17, 2020, at 14:40 GMT.

Who will represent Merus at the Jefferies Conference?

Dr. Bill Lundberg, the President and CEO of Merus, will represent the company at the Jefferies Conference.

Where can I watch the Merus presentation at the Jefferies Conference?

You can watch the live webcast of the Merus presentation on the company's Investors page.

What are Biclonics and Triclonics developed by Merus?

Biclonics^® and Triclonics™ are innovative multispecific antibodies designed by Merus to have features similar to conventional human monoclonal antibodies.